Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-12-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司第八届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 10th meeting of the 8th Supervisory Board of Jinling Pharmaceutical Co., Ltd. It details the meeting's convening, voting results on various proposals including equity incentive plans, and compliance with relevant laws and regulations. The content focuses on board-level decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (1687 characters) and it is an announcement of board resolutions, not a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2021-12-30 Chinese
金陵药业2021年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation and assessment of a 2021 restricted stock incentive plan by Jinling Pharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, feedback, and application of the assessment results related to the stock incentive plan. The content focuses on governance and management of the stock incentive plan, including performance targets and evaluation criteria for employees and executives. There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. The document is a governance-related policy document issued by the company's board and approved by the shareholders' meeting. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3277 characters, which is substantive and not a mere announcement or certification. Hence, the classification is CGR with high confidence.
2021-12-30 Chinese
金陵药业股份有限公司第八届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifteenth meeting of the eighth board of directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and decisions made, including approval of equity transfer, stock incentive plans, and authorization for further actions. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and governance matters. It also references related announcements to be made at shareholder meetings. Given the focus on board meeting resolutions and governance decisions, this fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a direct announcement of board meeting resolutions, not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2021-12-30 Chinese
金陵药业2021年限制性股票激励计划（草案）全文
Remuneration Information Classification · 95% confidence The document is titled "金陵药业股份有限公司 2021 年限制性股票激励计划（草案）" which translates to "Jinling Pharmaceutical Co., Ltd. 2021 Restricted Stock Incentive Plan (Draft)". It is a detailed draft plan for a restricted stock incentive program, including legal basis, scope, stock quantities, pricing, conditions for granting and lifting restrictions, and management structure. The document is lengthy (15,000 characters) and contains no financial statements or earnings data. It is not an annual or interim report, earnings release, or audit report. It is a corporate governance-related document focused on stock incentive plans for management and employees. This type of document fits best under "Remuneration Information (DEF 14A)" category, which covers reports detailing compensation and incentive plans for executives and directors. Therefore, the classification is DEF 14A with high confidence.
2021-12-30 Chinese
金陵药业独立董事关于公司第八届董事会第十五次会议审议的有关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including related party transactions, a restricted stock incentive plan, and the solicitation of proxy votes for a shareholders' meeting. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on governance, board decisions, and management proposals rather than financial results or audit findings. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation document itself but an independent opinion related to board meeting resolutions. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or senior management matters. The document length is 2162 characters, indicating it is a detailed opinion rather than a brief announcement or report publication notice.
2021-12-30 Chinese
金陵药业2021年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed summary of a 2021 restricted stock incentive plan (股权激励计划) for Jinling Pharmaceutical Co., Ltd. It includes legal bases, plan objectives, management structure, scope and criteria for incentive recipients, stock source and quantity, pricing, vesting and lock-up periods, performance targets, and procedural details. The content is focused on management compensation and equity incentive arrangements rather than financial results, audit opinions, or shareholder meeting materials. It is not a financial report, earnings release, or regulatory announcement. The document is a comprehensive management report on stock-based compensation plans, which fits the category of Remuneration Information (DEF 14A) filings that detail executive and director compensation plans and incentives.
2021-12-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.